MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
41.52
+1.35
+3.36%
After Hours: 39.84 -1.68 -4.05% 18:12 12/31 EST
OPEN
40.14
PREV CLOSE
40.17
HIGH
41.60
LOW
39.84
VOLUME
772.24K
TURNOVER
--
52 WEEK HIGH
46.01
52 WEEK LOW
14.80
MARKET CAP
3.35B
P/E (TTM)
-20.4825
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/29/2025 21:05
Weekly Report: what happened at CGON last week (1222-1226)?
Weekly Report · 12/29/2025 09:14
enGene Holdings: A Potential Oncology Entrant
Seeking Alpha · 12/26/2025 21:00
These Are the Most and Least Likely Biotech Takeover Targets for 2026
TipRanks · 12/23/2025 19:37
Here are the most and least likely M&A targets in biotech, according to Truist
Seeking Alpha · 12/23/2025 18:26
3 ‘Strong Buy’ Stocks to Buy Today,12/23/2025, According to Top Analysts
TipRanks · 12/23/2025 12:39
CG Oncology Undervalued Going Into A Busy 2026
Seeking Alpha · 12/23/2025 09:43
CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating
TipRanks · 12/22/2025 18:45
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.